tradingkey.logo

Merus NV

MRUS
查看詳細走勢圖
90.000USD
0.0000.00%
收盤 02/06, 16:00美東報價延遲15分鐘
6.83B總市值
虧損本益比TTM

Merus NV

90.000
0.0000.00%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

0.00%

1月

0.00%

6月

+41.98%

今年開始到現在

0.00%

1年

+118.18%

查看詳細走勢圖

TradingKey 股票評分

由於缺少必要的數據,暫時無法對該公司進行評分

Merus NV新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Merus NV簡介

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
公司代碼MRUS
公司Merus NV
CEOLundberg (Sven Ante)
網址https://merus.nl/
KeyAI